Premium
The efficacy of additive tolterodine extended release for 1‐year in older men with storage symptoms and clinical benign proastatic hyperplasia
Author(s) -
Chung ShiuDong,
Chang HsiaoChun,
Chiu Bin,
Liao ChunHou,
Kuo HannChorng
Publication year - 2011
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.20923
Subject(s) - medicine , tolterodine , international prostate symptom score , urology , benign prostatic hyperplasia (bph) , lower urinary tract symptoms , prostate , hyperplasia , quality of life (healthcare) , overactive bladder , alternative medicine , nursing , pathology , cancer
Aim To determine the efficacy of toterodine extended release (ER) treatment for 1 year in older men with benign prostatic hyperplasia (BPH) and storage symptoms treated with alpha‐blockers and/or 5‐alpha‐reductase inhibitors (5ARI). Methods Men aged over 70 years with BPH/bladder outlet obstruction (BOO) and clinical storage symptoms were randomly treated with or without tolterodine ER in combination with alpha‐blockers and/or 5ARI for 12 months. Among them, 50 patients (group 1) received additive tolterodine extended release (ER) 4 mg q.d., another 87 patients (group 2) did not. All patients had a baseline and 12th month post‐treatment evaluation, which comprised of uroflowmetry, post‐void residual (PVR) volume, International Prostate Symptom Score (IPSS), and quality of life index (QoL‐I), transrectal ultrasound of the prostate and serum prostate specific antigen. Results One hundred thirty‐seven of 153 enrolled patients with a mean age of 74.9 years completed the study. Treatment benefit demonstrated in both groups included deceased total, voiding and storage IPSS scores, increased peak urinary flow rate and deceased QoL‐I. Inter‐group difference was only observed on the storage domain of IPSS score ( P = 0.012). The mean PVR after treatment did not significantly differ between two groups. Two patients of group 1 and three of group 2 developed acute urinary retention. Among group 1, six patients discontinued tolterodine ER for intolerable dry mouth; among group 2, three patients reported dizziness. Conclusions This longer comparative study indicated that additive treatment with tolterodine ER in older men with BPH/BOO and significant storage symptoms is a beneficial and safe therapeutic option. Neurourol. Urodynam. 30:568–571, 2011. © 2011 Wiley‐Liss, Inc.